Literature DB >> 29134771

Detection of β-Amyloid by Sialic Acid Coated Bovine Serum Albumin Magnetic Nanoparticles in a Mouse Model of Alzheimer's Disease.

Seyedmehdi Hossaini Nasr1, Hovig Kouyoumdjian1,2, Christiane Mallett3, Sherif Ramadan1,4, David C Zhu3, Erik M Shapiro3,5, Xuefei Huang1,5.   

Abstract

The accumulation and formation of β-amyloid (Aβ) plaques in the brain are distinctive pathological hallmarks of Alzheimer's disease (AD). Designing nanoparticle (NP) contrast agents capable of binding with Aβ highly selectively can potentially facilitate early detection of AD. However, a significant obstacle is the blood brain barrier (BBB), which can preclude the entrance of NPs into the brain for Aβ binding. In this work, bovine serum albumin (BSA) coated NPs are decorated with sialic acid (NP-BSAx -Sia) to overcome the challenges in Aβ imaging in vivo. The NP-BSAx -Sia is biocompatible with high magnetic relaxivities, suggesting that they are suitable contrast agents for magnetic resonance imaging (MRI). The NP-BSAx -Sia binds with Aβ in a sialic acid dependent manner with high selectivities toward Aβ deposited on brains and cross the BBB in an in vitro model. The abilities of these NPs to detect Aβ in vivo in human AD transgenic mice by MRI are evaluated without the need to coinject mannitol to increase BBB permeability. T2 *-weighted MRI shows that Aβ plaques in mouse brains can be detected as aided by NP-BSAx -Sia, which is confirmed by histological analysis. Thus, NP-BSAx -Sia is a promising new tool for noninvasive in vivo detection of Aβ plaques.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  blood brain barrier; magnetic nanoparticles; magnetic resonance imaging; sialic acid; β-amyloid

Mesh:

Substances:

Year:  2017        PMID: 29134771      PMCID: PMC5773361          DOI: 10.1002/smll.201701828

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  70 in total

Review 1.  Pharmaceutical strategies utilizing recombinant human serum albumin.

Authors:  Victor Tuan Giam Chuang; Ulrich Kragh-Hansen; Masaki Otagiri
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

2.  Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging.

Authors:  Niels Braakman; Jörg Matysik; Sjoerd G van Duinen; Fons Verbeek; Reinhard Schliebs; Huub J M de Groot; A Alia
Journal:  J Magn Reson Imaging       Date:  2006-09       Impact factor: 4.813

3.  Binding of amyloid beta-peptide to ganglioside micelles is dependent on histidine-13.

Authors:  Mike P Williamson; Yu Suzuki; Nathan T Bourne; Tetsuo Asakura
Journal:  Biochem J       Date:  2006-08-01       Impact factor: 3.857

Review 4.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

Review 5.  Morphology of blood-brain interfaces.

Authors:  M W Brightman
Journal:  Exp Eye Res       Date:  1977       Impact factor: 3.467

6.  Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice.

Authors:  Alexandra Petiet; Mathieu Santin; Anne Bertrand; Christopher J Wiggins; Fanny Petit; Diane Houitte; Philippe Hantraye; Jesus Benavides; Thomas Debeir; Thomas Rooney; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-04-30       Impact factor: 4.673

7.  Amyloid-beta detection with saccharide immobilized gold nanoparticle on carbon electrode.

Authors:  Miyuki Chikae; Tomohiro Fukuda; Kagan Kerman; Koutarou Idegami; Yoshiko Miura; Eiichi Tamiya
Journal:  Bioelectrochemistry       Date:  2008-06-12       Impact factor: 5.373

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging.

Authors:  Youssef Zaim Wadghiri; Einar M Sigurdsson; Marcin Sadowski; James I Elliott; Yongsheng Li; Henrieta Scholtzova; Cheuk Ying Tang; Gilbert Aguinaldo; Miguel Pappolla; Karen Duff; Thomas Wisniewski; Daniel H Turnbull
Journal:  Magn Reson Med       Date:  2003-08       Impact factor: 4.668

Review 10.  The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events.

Authors:  Kaj Blennow; Henrik Zetterberg
Journal:  Front Neurosci       Date:  2015-09-29       Impact factor: 4.677

View more
  7 in total

1.  Decorated Superparamagnetic Iron Oxide Nanoparticles with Monoclonal Antibody and Diethylene-Triamine-Pentaacetic Acid Labeled with Thechnetium-99m and Galium-68 for Breast Cancer Imaging.

Authors:  Marta de Souza Albernaz; Sergio Hiroshi Toma; Jeff Clanton; Koiti Araki; Ralph Santos-Oliveira
Journal:  Pharm Res       Date:  2018-01-05       Impact factor: 4.200

Review 2.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

3.  Phosphorylation of covalent organic framework nanospheres for inhibition of amyloid-β peptide fibrillation.

Authors:  Linli Yao; Zhe Zhou; Suxiao Wang; Qichao Zou; Hang-Xing Wang; Li-Xin Ma; Shengfu Wang; Xiuhua Zhang
Journal:  Chem Sci       Date:  2022-04-22       Impact factor: 9.969

Review 4.  Nanomaterials for Drug Delivery to the Central Nervous System.

Authors:  Daniel Mihai Teleanu; Irina Negut; Valentina Grumezescu; Alexandru Mihai Grumezescu; Raluca Ioana Teleanu
Journal:  Nanomaterials (Basel)       Date:  2019-03-05       Impact factor: 5.076

Review 5.  Sialometabolism in Brain Health and Alzheimer's Disease.

Authors:  Punam Rawal; Liqin Zhao
Journal:  Front Neurosci       Date:  2021-03-30       Impact factor: 4.677

Review 6.  Magnetic Resonance Imaging in Animal Models of Alzheimer's Disease Amyloidosis.

Authors:  Ruiqing Ni
Journal:  Int J Mol Sci       Date:  2021-11-25       Impact factor: 5.923

Review 7.  Nanomedicines in the Management of Alzheimer's Disease: Current View and Future Prospects.

Authors:  Hitesh Chopra; Shabana Bibi; Inderbir Singh; Mohammad Amjad Kamal; Fahadul Islam; Fahad A Alhumaydhi; Talha Bin Emran; Simona Cavalu
Journal:  Front Aging Neurosci       Date:  2022-07-08       Impact factor: 5.702

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.